Protocol·One

Semaglutide · For women over 40

Semaglutide for women over 40

Perimenopausal weight gain. Wegovy / Ozempic?

S-Tier Weight Loss Subgroup analysis

New to peptides? Start with the foundations ->

Why people use Semaglutide for women over 40

Perimenopausal weight gain. Wegovy / Ozempic? The short answer: yes, this is one of the more-discussed uses for Semaglutide - but the evidence quality and the right protocol depend on what you're actually trying to fix.

This page covers what's known, what's not, and what the editorial take is for normal humans considering Semaglutide for women over 40.

What the evidence says

Evidence tier: Subgroup analysis. Trial subgroup data supports use in this population; broader trial design didn't target the subgroup.

  • Largest demographic on Wegovy by far.
  • Effective across the perimenopausal transition.
  • Often paired with hormone therapy with no documented interaction issues.

Protocol notes

Standard dosing. Coordinate with PCP or gynecologist if on HT.

Always with a sports-medicine doctor, telehealth provider, or specialist sign-off. Self-experimenting on injection schedules without clinical input is the most common way people waste money and get hurt.

What to skip

  • Vendors without a Certificate of Analysis (COA). Random gym-bro vendors with no third-party testing. The peptide market has a quality-control problem; the answer is COA per peptide, every time.
  • Pre-mixed blends from non-pharmacy sources. Compounding pharmacies that produce pre-mixed combinations with COAs are fine. Random vendor "stack vials" are not.
  • Massively over-dosed protocols. More is rarely better with peptides. Receptor saturation is real. Stick to evidence-based dosing.

Where to go next

Subscribe to the dispatch

The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Free. 5-min read. Broken down for normal humans.

-> Subscribe free

Last reviewed · 2026-05-07 · Page generated by Protocol One matrix engine